eMedicine Specialties > Hematology > Disorders of Lymphocytic Function

Combined B-Cell and T-Cell Disorders: Differential Diagnoses & Workup

Author: Francisco J Hernandez-Ilizaliturri, MD, Assistant Professor, Departments of Medicine and Immunology, Roswell Park Cancer Institute, State University of New York at Buffalo
Coauthor(s): Mohammad Muhsin Chisti, MD, Staff Physician, Department of Internal Medicine, Sisters of Charity, University at Buffalo State University of New York (SUNY) School of Medicine and Biomedical Sciences; Issam Makhoul, MD, Associate Professor, Department of Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences; David Claxton, MD, Assistant Professor, Department of Internal Medicine, Section of Hematology-Oncology, Hershey Medical Center, Pennsylvania State University; James O Ballard, MD, Kienle Chair for Humane Medicine, Professor, Departments of Humanities, Medicine, and Pathology, Division of Hematology/Oncology, Milton S Hershey Medical Center, Pennsylvania State University College of Medicine
Contributor Information and Disclosures

Updated: Jun 24, 2008

Differential Diagnoses

Agammaglobulinemia
Lymphohistiocytosis
Atopic Dermatitis
Lymphoproliferative Disorders
Cartilage-Hair Hypoplasia
Perinatally transmitted HIV disease
Complement Deficiencies
T-Cell Disorders
Congenital TORCH (Toxoplasma, Rubella, Cytomegalovirus, Herpes Simplex)
Wiskott-Aldrich Syndrome
Cystic Fibrosis
X-linked Immunodeficiency With Hyper IgM
DiGeorge Syndrome
Human Immunodeficiency Virus Infection
Hyperimmunoglobulinemia E (Job) Syndrome

Other Problems to Be Considered

Patients with combined B-cell and T-cell disorders present with symptoms similar to those of patients with pure B-cell disorders; however, the association of infections controlled by cellular immunity should point to the possibility of a combined deficiency in both humoral and cellular immunity. Exclude HIV infection with appropriate testing.

Workup

Laboratory Studies

The diagnosis of SCID should be suspected in children with any of the following conditions:

  • Unexplained lymphopenia
  • Failure to thrive
  • Chronic diarrhea
  • Recurrent severe episodes of RSV, HSV, VZV, measles, influenza, or parainfluenza
  • A family history of SCID
Suspected patients require complete evaluation of specific humoral and cellular immunity, which includes measurement of immunoglobulin levels, antibody titers, lymphocyte subsets, and assessment of T-cell function. This can be done via evaluating the responses to mitogens in vitro.

There is no population screening for SCID at present. The probable diagnosis of SCID is based on the following:

  • A T-cell count less than 20% of the lymphocytes, an absolute lymphocyte count of less than 3,000 cells/mm3, and a response to mitogens of less than 10% of the control or maternal T cells in the circulation
  • At this point, establish a molecular diagnosis and also consider the sex, family history, and phenotype of the patient.
  • Quantitative measurement of the serum immunoglobulins and IgG subclasses is necessary to confirm the diagnosis of B-cell deficiency. If, despite normal results, humoral immunodeficiency is suggested, the antibody response to specific antigens (polysaccharide or protein antigens) should be evaluated further. In patients with SCID presenting with recurrent infections in the first months of life, immunoglobulin levels are not helpful in the diagnosis, owing to the presence and persistence of maternal antibodies.

Levels of serum immunoglobulin are determined by serum protein electrophoresis.

  • Quantitative methods are used for the precise measurement of each immunoglobulin isotype. Enzyme-linked immunosorbent assays (ELISAs) are used for IgE quantitation.
  • Compare values to age-standardized reference ranges for each laboratory. The following are examples of values that are used for the adult population:
    • IgG1 – 500-1200 mg/dL
    • IgG2 – 200-600 mg/dL
    • IgG3 – 50-100 mg/dL
    • IgG4 – 20-100 mg/dL
    • IgM – 50-150 mg/dL
    • IgA1 – 50-200 mg/dL
    • IgA2 – 0-20 mg/dL
    • IgD – 0-40 mg/dL
    • IgE – 0-0.2 mg/dL
  • In most disorders involving IgG, the level is less than 200-250 mg/dL. levels of the other immunoglobulins vary depending on the underlying disease.
  • Immunoglobulin subclass deficiency is defined as a decrease of an IgG subclass greater than 2 standard deviations (SDs) below the normal mean for age.

Antibody response after immunization may be absent.

  • Check the antitetanus/diphtheria antibodies (IgG1), antipneumococcal polysaccharide antibodies (IgG2), and antirespiratory virus antibodies (IgG3) if the titers for the total immunoglobulins are within the reference ranges and the patient is unable to produce antibodies to specific antigens.
  • Antibody response is evaluated by measuring antitetanus and antipneumococcal titers 3-4 weeks after vaccination; a rise of 4-fold for antitetanus and 2-fold for antipneumococcal titers is considered normal.

The absence of isohemagglutinins is a significant finding that is suggestive of an immunoglobulin production problem. Evaluate IgM antibodies to A and B blood group antigens (isohemagglutinins) if the other test findings are within reference ranges and the patient is unable to mount a response to specific antigens.

Peripheral blood lymphocyte levels should be measured.

  • The lymphocyte count is higher in infancy and childhood than in adulthood. An absolute lymphocyte count of less than 280 per microliter (ie, 2 SDs below the mean) is abnormal.
  • The association of a low lymphocyte count with recurrent infections is very suggestive of immunodeficiency.

Lymphocyte phenotyping using flow cytometry analysis is the next step. The absolute number of B, T, and NK cells is more useful than percentages.

Measuring T-lymphocyte numbers and function may be necessary. Lymphocyte activation (CD45 RA/RO isoformic antigens) and T-cell receptor phenotype (TCR ab/gd lineage) determination may provide additional information regarding the type of immunodeficiency. For example, Omenn syndrome is characterized by a high number of T cells carrying TCRgd or CD45+. Determination of the helper (CD4) to suppressor (CD8) T-cell ratio is sometimes useful.

Cutaneous delayed-type hypersensitivity testing is used to evaluate the anamnestic response of cellular immunity to previously encountered antigens.

  • The test results are not reliable in children younger than age 1 year, and the response is frequently suppressed following viral and bacterial infections and after glucocorticoid therapy.
  • The results are determined by measuring the induration 48-72 hours following an intradermal injection of 0.1 mL of tetanus toxoid (at 1:100 dilution, 0.2 Loeffler U/0.1 mL), mumps skin test antigen, candidal antigen (at 1:100 dilution; if no reaction is present, use 1:10 dilution), tuberculin (0.1 mL containing 2-10 IU of purified protein derivative [PPD]), and trichophytin (1:30 dilution).
  • The test result is considered positive if the induration is greater than 5 mm (or >2 mm in children).
  • This test can be complemented by in vitro study of lymphocyte proliferation to different mitogens.

Results related to specific disorders are as follows:

  • XHM
    • The IgM measurement is markedly increased to levels frequently higher than 1000 mg/dL. Note: Normal levels do not exclude the diagnosis (in a study, normal levels were present in 29 of 55 patients with genetically proven XHM6 ). IgG, IgA, and IgE levels and the number of lymphocytes bearing these antibodies are decreased. An IgM response to antigen exposure is possible, but the IgG and IgA responses are absent or diminished. Cell-mediated immunity is defective in some patients despite a normal T-lymphocyte count. Chronic neutropenia may be present in some patients.
  • ADA deficiency
    • The erythrocyte deoxy-ATP level is increased in patients with ADA deficiency. The values in carriers are half to two thirds of the normal values of erythrocyte deoxy ATP. Lymphopenia is more severe than in other SCID syndromes (ie, <500/μ L). Although the number of B and NK cells is decreased, their function is quasinormal, and they normalize completely after bone marrow transplantation without pretransplantation chemotherapy.
  • RAG1 and RAG2 deficiency
    • B and T lymphocytes are completely absent. NK cells are the only circulating lymphocytes. Immunoglobulin levels are severely decreased.

Imaging Studies

  • Chest radiography
    • Sometimes, recurrent or chronic infections may lead to abnormal chest radiographic findings, such as interstitial infiltrates, bronchiectasis, emphysema, and scarring. Note: Normal chest radiographic findings do not exclude the presence of structural abnormalities.
    • A very common finding in SCID can be absence of a thymic shadow. (DiGeorge syndrome and other T-cell defects may also lack thymic tissue, but the presence of thymic tissue does not exclude SCID. Moreover, patients with SCID who have mutations in ZAP70 or CD3 typically have normal-sized thymuses.)
    • Patients with ADA deficiency typically show cupping and flaring of the costochondral junctions.

Other Tests

For a prenatal diagnosis, restriction fragment length polymorphism (RFLP)can help detect genetic defect carriers of XHM, WAS, and ADA deficiency using fetal blood, amnion cells, or chorionic villus tissue. Umbilical cord blood can be used in the prenatal diagnosis of some of these disorders.

T cells are absent in persons with XSCID. B cells and T cells are absent in patients with autosomal recessive SCID. "Bald" lymphocytes found on scanning electron microscopy are diagnostic of WAS. Red blood cell ADA is decreased in fetuses with ADA deficiency.

ADA deficiency can be evaluated by demonstrating the following:

  • Absent ADA levels in lysed erythrocytes
  • A marked increase in dATP levels in erythrocytes
  • A significant decrease in ATP concentration in red blood cells
  • Absent or extremely low levels of N-adenosylhomocysteine hydrolase in red blood cells
  • An increase in 2'-deoxyadenosine in urine and plasma

In AT, chromosomal karyotyping should reveal reciprocal translocations between chromosomes 7 and 14. Chromosomal instability testing is done to confirm AT and NBS to assess spontaneous and induced breakage. Diagnostic findings are absence or dysfunction of the ATM protein and mutations in the ATM gene.

Procedures

  • Bronchoscopy should be performed frequently for recurrent pulmonary infections.
  • Endoscopic biopsies should be performed to look for the extent and to identify the cause of the diarrhea.
  • Lymph node biopsy is not necessary for the diagnosis, although findings may indicate a paucity of T- and B-cells and a lack of germinal centers8

More on Combined B-Cell and T-Cell Disorders

Overview: Combined B-Cell and T-Cell Disorders
Differential Diagnoses & Workup: Combined B-Cell and T-Cell Disorders
Treatment & Medication: Combined B-Cell and T-Cell Disorders
Follow-up: Combined B-Cell and T-Cell Disorders
References
Further Reading

References

  1. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet?. J Clin Invest. Jun 2007;117(6):1456-65. [Medline][Full Text].

  2. Khiong K, Murakami M, Kitabayashi C, et al. Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model. J Clin Invest. May 2007;117(5):1270-81. [Medline][Full Text].

  3. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. Apr 28 2000;288(5466):669-72. [Medline].

  4. Sinha S, Schwartz RA. Severe combined immunodeficiency. eMedicine from WebMD. Updated August 21, 2006. Accessed June 11, 2008. Available at http://www.emedicine.com/ped/TOPIC2083.HTM.

  5. Bonilla FA, Geha RS. 2. Update on primary immunodeficiency diseases. J Allergy Clin Immunol. Feb 2006;117(2 suppl mini-primer):S435-41. [Medline].

  6. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. Jul 1997;131(1 pt 1):47-54. [Medline].

  7. Ridanpaa M, van Eenennaam H, Pelin K, et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell. Jan 26 2001;104(2):195-203. [Medline][Full Text].

  8. Chin T, Alonazi N. B-cell and T-cell combined disorders. eMedicine from WebMD. Updated April 5, 2007. Accessed June 11, 2008. Available at http://www.emedicine.com/ped/TOPIC191.HTM.

  9. Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. J Pediatr. Jun 1999;134(6):740-8. [Medline].

  10. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. Feb 18 1999;340(7):508-16. [Medline][Full Text].

  11. Gennery AR, Flood TJ, Abinun M, Cant AJ. Bone marrow transplantation does not correct the hyper IgE syndrome. Bone Marrow Transplant. Jun 2000;25(12):1303-5. [Medline].

  12. Kohn DB. Adenosine deaminase gene therapy protocol revisited. Mol Ther. Feb 2002;5(2):96-7. [Medline][Full Text].

  13. Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science. Aug 3 2007;317(5838):617-9. [Medline].

  14. Husain M, Grunebaum E, Naqvi A, et al. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr. Jul 2007;151(1):93-5. [Medline].

  15. Atluri S, Neville K, Davis M, et al. Epstein-Barr-associated leiomyomatosis and T-cell chimerism after haploidentical bone marrow transplantation for severe combined immunodeficiency disease. J Pediatr Hematol Oncol. Mar 2007;29(3):166-72. [Medline].

  16. Chapel H, Puel A, von Bernuth H, Picard C, Casanova JL. Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. Clin Infect Dis. May 1 2005;40(9):1227-31. [Medline][Full Text].

  17. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. Sep 26 2002;419(6905):395-9. [Medline].

  18. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. Dec 1999;93(3):190-7. [Medline].

  19. Cooper MD, Lanier LL, Conley ME, Puck JM. Immunodeficiency disorders. Hematology Am Soc Hematol Educ Program. 2003;314-30. [Medline][Full Text].

  20. Creagh EM, Conroy H, Martin SJ. Caspase-activation pathways in apoptosis and immunity. Immunol Rev. Jun 2003;193:10-21. [Medline].

  21. Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. Feb 2005;203:98-109. [Medline].

  22. Gennery AR, Cant AJ. Diagnosis of severe combined immunodeficiency. J Clin Pathol. Mar 2001;54(3):191-5. [Medline][Full Text].

  23. Hadzic N, Pagliuca A, Rela M, et al. Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. N Engl J Med. Feb 3 2000;342(5):320-4. [Medline][Full Text].

  24. Hermanns P, Bertuch AA, Bertin TK, et al. Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. Hum Mol Genet. Dec 1 2005;14(23):3723-40. [Medline][Full Text].

  25. Kohn DB. Gene therapy for genetic haematological disorders and immunodeficiencies. J Intern Med. Apr 2001;249(4):379-90. [Medline][Full Text].

  26. Kuska B. Wiskott-Aldrich syndrome: molecular pieces slide into place. J Natl Cancer Inst. Jan 5 2000;92(1):9-11. [Medline][Full Text].

  27. Notarangelo LD, Forino C, Mazzolari E. Stem cell transplantation in primary immunodeficiencies. Curr Opin Allergy Clin Immunol. Dec 2006;6(6):443-8. [Medline].

  28. Revy P, Malivert L, de Villartay JP. Cernunnos-XLF, a recently identified non-homologous end-joining factor required for the development of the immune system. Curr Opin Allergy Clin Immunol. Dec 2006;6(6):416-20. [Medline].

  29. Torgerson TR, Ochs HD. Regulatory T cells in primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol. Dec 2007;7(6):515-21. [Medline].

  30. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. Oct 1 1997;90(7):2680-9. [Medline][Full Text].

Keywords

severe combined immunodeficiency, SCID, X-linked severe combined immunodeficiency, XSCID, combined immunodeficiency, JAK3 deficiency, adenosine deaminase deficiency, ADA deficiency, reticular dysgenesis, X-linked hyper-IgM syndrome, X-linked immunodeficiency with hyper IgM, XHM, common lymphoid progenitor, CLP, X-linked agammaglobulinemia, XLA, cartilage-hair hypoplasia, CHH, malnutrition, HIV infection, human immunodeficiency virus infection,

bacterial pneumonia, viral pneumonia, Pneumocystis carinii infection, infection, PCP, cytomegalovirus infection, CMV infection, disseminated bacille Calmette-Guerin infection, disseminated BCG infection, atypical mycobacterial infection, skin candidiasis, opportunistic infection, failure to thrive, FTT, short-limbed dwarfism, Omenn syndrome, Wiskott-Aldrich syndrome, WAS, common variable immunodeficiency, CVID

Contributor Information and Disclosures

Author

Francisco J Hernandez-Ilizaliturri, MD, Assistant Professor, Departments of Medicine and Immunology, Roswell Park Cancer Institute, State University of New York at Buffalo
Francisco J Hernandez-Ilizaliturri, MD is a member of the following medical societies: American Association for Cancer Research and American Society of Hematology
Disclosure: Nothing to disclose.

Coauthor(s)

Mohammad Muhsin Chisti, MD, Staff Physician, Department of Internal Medicine, Sisters of Charity, University at Buffalo State University of New York (SUNY) School of Medicine and Biomedical Sciences
Mohammad Muhsin Chisti, MD is a member of the following medical societies: American College of Physicians and Medical Society of the State of New York
Disclosure: Nothing to disclose.

Issam Makhoul, MD, Associate Professor, Department of Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences
Issam Makhoul, MD is a member of the following medical societies: American Society of Clinical Oncology and American Society of Hematology
Disclosure: Nothing to disclose.

David Claxton, MD, Assistant Professor, Department of Internal Medicine, Section of Hematology-Oncology, Hershey Medical Center, Pennsylvania State University
Disclosure: Nothing to disclose.

James O Ballard, MD, Kienle Chair for Humane Medicine, Professor, Departments of Humanities, Medicine, and Pathology, Division of Hematology/Oncology, Milton S Hershey Medical Center, Pennsylvania State University College of Medicine
James O Ballard, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Heart Association, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Medical Editor

Charles S Greenberg, MD, Director of Thrombosis and Transglutaminase Research Laboratory, Professor, Departments of Pathology and Medicine, Division of Hematology/Oncology, Duke University Medical Center
Charles S Greenberg, MD is a member of the following medical societies: American Society of Hematology and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Marcel E Conrad, MD, (Retired) Distinguished Professor of Medicine, University of South Alabama
Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, and Southwest Oncology Group
Disclosure: No financial interests None None

CME Editor

Rajalaxmi McKenna, MD, FACP, Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.